RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

Upcomers vs DeiFunded

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

UPCM

Upcomers

EST. 2023

DEIF

DeiFunded

UPCOMERS

METRIC

DEIFUNDED

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

—

MAX FUNDING

—

MIN COST

—

PAYOUT DAYS

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

UPCOMERS DETAILS

STEPS: -phase

DEIFUNDED DETAILS

STEPS: -phase

Upcomers PROS

+Czech Republic is an EU-member jurisdiction, which may offer relevant regulatory context for European traders.
+No further data is available to substantiate additional pros at this time.
+No platform or market data is provided to assess trading conditions.
+No funding or cost data is available to compare against industry benchmarks.

Upcomers CONS

−Founded in 2023, making Upcomers a very new firm with minimal operational track record.
−No profit split, drawdown, funding, or challenge cost data is available for industry comparison.
−Lack of transparency around key metrics makes it very difficult for traders to make informed decisions.

DeiFunded PROS

+No data is available to identify any pros for DeiFunded at this time.
+No platform or market information is provided to assess trading conditions.
+No funding or cost data is available to compare against industry benchmarks.
+No profit split or payout data exists to evaluate trader compensation.

DeiFunded CONS

−No data whatsoever is available for DeiFunded, making any evaluation impossible.
−Complete absence of key metrics such as drawdown, profit split, and funding is a significant transparency concern.
−Traders have no basis for comparison against industry averages with zero data disclosed.

PROPDNA VERDICT